Company profile for Crossject

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

All of Crossject's employees work every day as a team to develop innovative life-saving solutions and make them a reality for patients. Our approach to the administration of emergency medicines mobilizes not only our teams but also our industrial and financial partners to act on a patient life-saving mission across the world. From the solid foundation of its unmatched technology, Crossject aims to become the world's leading p...
All of Crossject's employees work every day as a team to develop innovative life-saving solutions and make them a reality for patients. Our approach to the administration of emergency medicines mobilizes not only our teams but also our industrial and financial partners to act on a patient life-saving mission across the world. From the solid foundation of its unmatched technology, Crossject aims to become the world's leading pharmaceutical laboratory for emergency needle free auto-injectables.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
Parc MAZEN-SULLY, 6-8 rue Pauline Kergomard, Dijon, Bourgogne 21000
Telephone
Telephone
+33 (0)3 80 54 98 50
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/14/3188556/0/en/CROSSJECT-completes-5-million-financing-with-Vatel-Capital.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/09/22/3153626/0/en/CROSSJECT-Secures-Additional-BARDA-Funding-for-the-Progressive-Developmental-and-FDA-Authorization-of-the-ZEPIZURE-ZENEO-Midazolam.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/08/04/3126727/0/en/CROSSJECT-remains-engaged-during-the-summer-break.html

GLOBENEWSWIRE
04 Aug 2025

https://www.globenewswire.com/news-release/2025/06/24/3104583/0/en/CROSSJECT-announces-a-successful-capital-increase-of-5-7-million-following-full-exercise-of-the-extension-clause.html

GLOBENEWSWIRE
24 Jun 2025

https://www.globenewswire.com/news-release/2025/06/11/3097270/0/en/CROSSJECT-advances-on-the-development-of-ZEPIZURE-Junior-its-solution-for-epilepsy-crises-in-children.html

GLOBENEWSWIRE
11 Jun 2025

https://www.globenewswire.com/news-release/2025/06/04/3093932/0/en/Launch-of-a-capital-increase-with-preferential-subscription-rights-for-nearly-5-million-euros.html

GLOBENEWSWIRE
04 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty